Abbonarsi

A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. - 31/08/22

Doi : 10.1016/j.biopha.2022.113499 
Yasser Mohamed a, b , Yousra A. El-Maradny a, c , Ahmed K. Saleh d, AbdElAziz A. Nayl e, , Hamada El-Gendi f, , Esmail M. El-Fakharany a,
a Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), New Borg EL-Arab, Alexandria 21934, Egypt 
b Laboratory of Kafr El-Sheikh Fever Hospital, Kafr El-Sheikh Fever Hospital, 33511 Kafr El-Sheikh, Egypt 
c Microbiology Department, High Institute of Public Health, Alexandria University, Alexandria 21526, Egypt 
d Cellulose and Paper Department, National Research Centre, El-Tahrir St., Dokki, P.O. 12622, Giza, Egypt 
e Department of Chemistry, College of Science, Jouf University, Sakaka 72341, Al Jouf, Saudi Arabia 
f Bioprocess Development Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Universities and Research Institutes zone, New Borg El-Arab, Alexandria 21934, Egypt 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

The healthy immune system eliminates pathogens and maintains tissue homeostasis through extraordinarily complex networks with feedback systems while avoiding potentially massive tissue destruction. Many parameters influence humoral and cellular vaccine responses, including intrinsic and extrinsic, environmental, and behavioral, nutritional, perinatal and administrative parameters. The relative contributions of persisting antibodies and immune memory as well as the determinants of immune memory induction, to protect against specific diseases are the main parameters of long-term vaccine efficacy. Natural and vaccine-induced immunity and monoclonal antibody immunotherapeutic, may be evaded by SARS-CoV-2 variants. Besides the complications of the production of COVID-19 vaccinations, there is no effective single treatment against COVID-19. However, administration of a combined treatment at different stages of COVID-19 infection may offer some cure assistance. Combination treatment of antiviral drugs and immunomodulatory drugs may reduce inflammation in critical COVID-19 patients with cytokine release syndrome. Molnupiravir, remdesivir and paxlovid are the approved antiviral agents that may reduce the recovery time. In addition, immunomodulatory drugs such as lactoferrin and monoclonal antibodies are used to control inflammatory responses in their respective auto-immune conditions. Therefore, the widespread occurrence of highly transmissible variants like Delta and Omicron indicates that there is still a lot of work to be done in designing efficient vaccines and medicines for COVID-19. In this review, we briefly discussed the immunological response against SARS-CoV-2 and the vaccines approved by the World Health Organization (WHO) for COVID-19, their mechanisms, and side effects. Moreover, we mentioned various treatment trials and strategies for COVID-19.

Il testo completo di questo articolo è disponibile in PDF.

Graphical Abstract




ga1

Il testo completo di questo articolo è disponibile in PDF.

Highlights

Available vaccines and treatments in COVID-19 management of, including their effect against SARS-CoV-2 variants of concern.
Some vaccines against SARS-CoV-2 are under emergency approval, and the mRNA vaccine shows the most effective technique.
Paxlovid, molnupiravir, and remdesivir are the currently effective antiviral agents against Omicron subvariants of SARS-CoV-2.
Bebtelovimab is the only monoclonal antibody that is active against all Omicron subvariants.
Some supportive treatments against SARS-CoV-2 such as lactoferrin show immunomodulatory and anti-inflammatory effects.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : COVID-19, Antiviral, Immunomodulators, Vaccination, Treatment

Abbreviations : +ssRNA, 3CL, ACE2, CCCs, ChAd, CRS, DPP, GRAS, HSPGs, IL-6, mAb, miRNA, PAMPs, PRRs, RdRp, SARS-CoV-2, SSRI, Th, TLRs, Tregs, VLPs, VOCs


Mappa


© 2022  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 153

Articolo 113499- settembre 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • ZEB1: Catalyst of immune escape during tumor metastasis
  • Jiahui Lu, Fei Fei, Chenxi Wu, Jie Mei, Junying Xu, Peihua Lu
| Articolo seguente Articolo seguente
  • Spatiotemporal dynamics of the cellular components involved in glial scar formation following spinal cord injury
  • Ce Zhang, Jianning Kang, Xiaodi Zhang, Ying Zhang, Nana Huang, Bin Ning

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.